TWI382845B - Cuscuta sp. extract and method for preparing the same and uses of cuscuta sp. - Google Patents
Cuscuta sp. extract and method for preparing the same and uses of cuscuta sp. Download PDFInfo
- Publication number
- TWI382845B TWI382845B TW99116803A TW99116803A TWI382845B TW I382845 B TWI382845 B TW I382845B TW 99116803 A TW99116803 A TW 99116803A TW 99116803 A TW99116803 A TW 99116803A TW I382845 B TWI382845 B TW I382845B
- Authority
- TW
- Taiwan
- Prior art keywords
- extract
- plant
- medicinal
- dodder
- camptothecin
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims description 75
- 238000000034 method Methods 0.000 title claims description 43
- 241000207901 Cuscuta Species 0.000 title description 18
- 241000196324 Embryophyta Species 0.000 claims description 85
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 69
- 240000007371 Cuscuta campestris Species 0.000 claims description 55
- 239000007788 liquid Substances 0.000 claims description 37
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 31
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 31
- 229940127093 camptothecin Drugs 0.000 claims description 31
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 31
- 201000005787 hematologic cancer Diseases 0.000 claims description 30
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 30
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 23
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 20
- 241001609679 Cuscuta japonica Species 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 241000759909 Camptotheca Species 0.000 claims description 7
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 240000006550 Lantana camara Species 0.000 claims description 3
- 240000001829 Catharanthus roseus Species 0.000 claims description 2
- 241000219122 Cucurbita Species 0.000 claims description 2
- 244000259191 Duranta erecta Species 0.000 claims description 2
- 235000005206 Hibiscus Nutrition 0.000 claims description 2
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims description 2
- 244000126968 Kalanchoe pinnata Species 0.000 claims description 2
- 240000000249 Morus alba Species 0.000 claims description 2
- 235000008708 Morus alba Nutrition 0.000 claims description 2
- 241000985694 Polypodiopsida Species 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 12
- 244000004281 Eucalyptus maculata Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 10
- 241000759905 Camptotheca acuminata Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000239226 Scorpiones Species 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000219927 Eucalyptus Species 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001635750 Cuscuta japonica var. japonica Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- 241001135067 Cuscuteae Species 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 240000000231 Ficus thonningii Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 244000000042 obligate parasite Species 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
本發明係關於一種菟絲子(Cuscuta sp.)萃取物及其製備方法,尤其關於一種含藥性成分之菟絲子萃取物及其製備方法,以及菟絲子於提取植物中之藥性成分的應用。The present invention relates to a Cuscuta sp. extract and a preparation method thereof, in particular to a medicinal component-containing silk extract, a preparation method thereof, and an application of the medicinal component of the scorpion in extracting plants.
於大規模之草藥製程中,通常須經由大量栽種具藥性成分之植物,待其生長至成熟期後採收,再進行諸如植株乾燥、研磨、萃取、以及濃縮等步驟,以製備包含藥性成分之植物萃取物。於上述過程中,須要大面積之土地栽種植物,且須經一定時間等待植物成熟,而於植物採收後尚須重新進行栽種。此外,後續之萃取及濃縮須繁複的步驟,且會消耗大量的有機溶劑。因此,傳統的草藥製程相當耗時費力,且成本高、效率低,甚至會造成環境污染。In the large-scale herbal process, it is usually necessary to plant a plant having a medicinal ingredient, and to harvest it after the growth period, and then perform steps such as drying, grinding, extracting, and concentrating to prepare a drug-containing component. Plant extracts. In the above process, a large area of land is required to plant the plant, and it is necessary to wait for the plant to mature after a certain period of time, and the plant must be replanted after harvesting. In addition, subsequent extraction and concentration requires complicated steps and consumes a large amount of organic solvent. Therefore, the traditional herbal process is quite time consuming and laborious, and the cost is high, the efficiency is low, and even environmental pollution is caused.
菟絲子(Cuscuta sp.)為一種具有特殊生理構造之寄生性旋花科(Convolvulaceae )植物。由於菟絲子葉不含有葉綠體,無法行光合作用來製造養分,故必須纏繞寄生於寄主植物上,藉由菟絲子莖上之吸器(haustorium)插入該寄主植物之韌皮部中,以與菟絲子本身之韌皮部相連結,並透過吸取該寄主植物之營養成分以維持生命及生長。此外,菟絲子不具寄主專一性(host specificity),其可任意地寄生於各種植物上,且具有自我纏繞寄生之自我寄生(self-parasitim)能力,甚至具有寄生在別種寄生植物之重寄生(hyperparasitism)能力。有關菟絲子之寄生特性,可參見如Birschwilkset al. Transfer of phloem-mobile substances from the host plants to the holoparasiteCuscuta sp.Journal of Experimental Botany . 57: 911-921(2006),該文獻內容併於此處以供參考。 Cuscuta sp. is a parasitic Convolvulaceae plant with a special physiological structure. Since the cotyledons do not contain chloroplasts and cannot be used for photosynthetic nutrients, they must be entangled in the host plants, and inserted into the phloem of the host plant by the haustorium on the stalks of the stalks to connect with the phloem of the dodder itself. And maintain the life and growth by absorbing the nutrients of the host plant. In addition, dodder has no host specificity, it can be parasitic on various plants arbitrarily, and has self-parasitic self-parasitim ability, even parasitic on other parasitic plants (hyperparasitism). ability. For the parasitic properties of Cuscuta, see, for example, Birschwilks et al. Transfer of phloem-mobile substances from the host plants to the holoparasite Cuscuta sp. Journal of Experimental Botany . 57: 911-921 (2006), the contents of which are here for reference.
本發明之發明人研究發現,將菟絲子寄生於具有藥性成分之植物上,可將藥性成分自植物吸取出來且留存於菟絲子中,得到含有藥性成分之菟絲子,有效自植物中提取藥性成份,免除前述傳統草藥製程之繁雜濃縮步驟及其它相關缺點。The inventors of the present invention have found that the dodder is parasitized on a plant having a medicinal component, and the medicinal component can be taken out from the plant and retained in the dodder, and the medicinal component can be obtained, and the medicinal component can be effectively extracted from the plant, thereby eliminating the aforementioned The complicated concentration steps of traditional herbal processes and other related disadvantages.
本發明之一目的在於提供一種製備菟絲子(Cuscuta sp.)萃取物之方法,包含:a)將菟絲子寄生於一藥用植物上並於其上生長;b)收集該菟絲子中之液體;以及c)使用一溶劑萃取該液體,以得到該萃取物;其中,該萃取物包含該藥用植物之至少一種藥性成分。較佳地,該藥用植物為喜樹或絞股藍。It is an object of the present invention to provide a method for preparing an extract of Cuscuta sp. comprising: a) parasiticly growing and growing on a medicinal plant; b) collecting the liquid in the dodder; And extracting the liquid using a solvent to obtain the extract; wherein the extract comprises at least one medicinal ingredient of the medicinal plant. Preferably, the medicinal plant is Camptotheca or Gynostemma pentaphyllum.
本發明之另一目的在於提供一種菟絲子萃取物,其係利用上述方法所製得。Another object of the present invention is to provide a dodder seed extract which is obtained by the above method.
本發明之又一目的在於提供一種從植物提取喜樹鹼及/或抗血癌成分之方法,包含:I)將菟絲子寄生於該植物上並於其上生長;II)收集該菟絲子中之液體;以及III)純化該液體以得到該喜樹鹼及/或抗血癌成分。It is still another object of the present invention to provide a method for extracting camptothecin and/or anti-blood cancer components from plants, comprising: I) parasitizing and growing on the plant; and II) collecting the liquid in the dodder; And III) purifying the liquid to obtain the camptothecin and/or anti-blood cancer component.
本發明之詳細技術及較佳實施態樣,將描述於以下內容中,以供本發明所屬領域具通常知識者據以明瞭本發明之特徵。The detailed description of the present invention and the preferred embodiments thereof will be described in the following description.
除非文中有另外說明,於本說明書中(尤其是在後述專利申請範圍中)所使用之「一」、「該」及類似用語應理解為包含單數及複數形式。此外,於本文中,「藥性成分」乙詞係指任何具有藥理活性之成分,例如化合物、醣類、酵素、萃取物等。The use of the terms "a", "an", and <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; In addition, in the present text, the term "medicinal ingredient" means any pharmacologically active ingredient such as a compound, a saccharide, an enzyme, an extract or the like.
菟絲子(Cuscuta sp.)為寄生性植物,其莖上之吸器可插入寄主植物之韌皮部中,吸取寄主植物之營養成分以維生。一般對於菟絲子之瞭解,僅知其具有吸取寄主植物之營養成分以維持生長之特性。本發明人研究發現,將菟絲子寄生於具有藥性成分之植物(即,藥用植物)上,可藉由菟絲子而自植物中提取藥性成分,將該藥性成分留存於菟絲子中,達到自然濃縮之效果,以獲得植物藥性成分。 Cuscuta sp. is a parasitic plant, and the stem of the stem can be inserted into the phloem of the host plant to absorb the nutrients of the host plant to survive. Generally, for the understanding of Dodder, it is only known that it has the characteristics of absorbing the nutrients of the host plant to maintain growth. The present inventors have found that the dodder is parasitic on a plant having a medicinal ingredient (ie, a medicinal plant), and the medicinal component can be extracted from the plant by the dodder, and the medicinal component is retained in the dodder to achieve the effect of natural concentration. To obtain botanical medicinal ingredients.
因此,本發明提供一種製備菟絲子萃取物之方法,包含:a)將菟絲子寄生於一藥用植物上並於其上生長;b)收集該菟絲子中之液體;以及c)使用一溶劑萃取該液體,以得到該萃取物;其中,該萃取物包含該藥用植物之至少一種藥性成分。Accordingly, the present invention provides a method of preparing a dodder seed extract comprising: a) parasitizing and growing a dodder on a medicinal plant; b) collecting the liquid in the dodder; and c) extracting the liquid using a solvent And obtaining the extract; wherein the extract comprises at least one medicinal ingredient of the medicinal plant.
本發明方法所使用之菟絲子可為各種品系之菟絲子,而無任何限制。舉例言之,可使用日本菟絲子(Cuscuta japonica Choisy var. japonica)或日本菟絲子的衍生種,例如台灣菟絲子(Cuscuta japonica Choisy var. formosana(Hayata) Yunck.),其在台灣所分布之各種菟絲子品系當中,最為常見且最容易取得。The dodder used in the method of the present invention may be a dodder of various strains without any limitation. For example, a Cuscuta japonica Choisy var. japonica or a Japanese genus, such as Cuscuta japonica Choisy var. formosana (Hayata) Yunck., which is distributed among various filth strains distributed in Taiwan, may be used. , the most common and the easiest to get.
於本發明方法之步驟a)中,可將菟絲子寄生於各種藥用植物上,例如:木本植物、草本植物、蕨類植物、及其組合;較佳係寄生於一選自以下群組之藥用植物上:喜樹(Camptotheca acuminate )、絞股藍(Gynostemma pentaphyllum )、桑椹(Morus alba L.)、長春花(Vinca rosea L.)、馬櫻丹(Lantana camara L.)、落地生根(Kalanchoe pinnata )、金露華(Duranta repens L.)、南瓜(Cucurbita spp. )、及其組合。In step a) of the method of the present invention, the dodder can be parasitized on various medicinal plants, such as woody plants, herbaceous plants, ferns, and combinations thereof; preferably, parasitic in a group selected from the group consisting of Medicinal plants: Camptotheca acuminate , Gynostemma pentaphyllum , Morus alba L., Vinca rosea L., Lantana camara L., Kalanchoe pinnata , Duranta repens L., Cucurbita spp. , and combinations thereof.
於步驟b)中,主要係收集菟絲子韌皮部中之液體,以取得藥用植物中之藥性成分。可採用任何物理方法以取得該液體。例如,可採用離心分離操作,自菟絲子分離得到該液體。視需要可先將所採集到之菟絲子切成小段,再進行離心分離,以提升收集效率。於不受理論限制之情形下,發明人相信由於菟絲子在寄生於藥用植物上後,其莖上會產生吸器並插入藥用植物之韌皮部中,使菟絲子本身之韌皮部與藥用植物之韌皮部相連,進而吸取藥用植物中之成分。然因藥用植物中之藥用成份並非菟絲子生長所需之成分,故被濃縮留存於菟絲子中,尤其留存於菟絲子韌皮部之液體中。In step b), the liquid in the phloem of the dodder is mainly collected to obtain the medicinal component in the medicinal plant. Any physical method can be employed to obtain the liquid. For example, the liquid can be separated from the silk by a centrifugal separation operation. If necessary, the collected silk seeds can be cut into small pieces and then centrifuged to improve the collection efficiency. Without being bound by theory, the inventors believe that since the dodder is parasitic on medicinal plants, a stem is produced on the stem and inserted into the phloem of the medicinal plant, so that the phloem of the dodder itself is connected to the phloem of the medicinal plant. And then extract the ingredients in the medicinal plants. However, since the medicinal component in the medicinal plant is not a component required for the growth of the dodder, it is concentrated and retained in the dodder, especially in the liquid of the phloem of the dodder.
於步驟c)中,可使用適當之溶劑對步驟b)所得到之菟絲子液體進行萃取,製得菟絲子萃取物。舉例言之,可使用選自以下群組之溶劑:水、甲醇、乙醇、丙醇、丁醇、氯仿、及其組合。較佳地,係採用選自以下群組之溶劑:水、甲醇、乙醇、丙醇、氯仿、及其組合。In step c), the dodder liquid obtained in step b) can be extracted with a suitable solvent to obtain a dodder extract. For example, a solvent selected from the group consisting of water, methanol, ethanol, propanol, butanol, chloroform, and combinations thereof can be used. Preferably, a solvent selected from the group consisting of water, methanol, ethanol, propanol, chloroform, and combinations thereof is employed.
可視需要於步驟c)輔以其他合宜之萃取手段(如超音波震盪等),以提高萃取效果。此外,可視需要重複步驟c),以儘可能分離菟絲子液體中之有效成分與無效成分,且儘可能萃取出所欲之藥性成分。It may be necessary to use step (c) in addition to other suitable extraction means (such as ultrasonic vibration, etc.) to enhance the extraction effect. In addition, step c) may be repeated as needed to separate as much as possible the active ingredient and the inactive ingredient in the liquid of the dodder, and extract the desired pharmaceutical ingredient as much as possible.
於步驟c)中,可於進行萃取前,先乾燥步驟b)所收集之液體以獲得一乾燥物,再使用上述溶劑對該乾燥物進行萃取。In the step c), the liquid collected in the step b) may be dried to obtain a dried product before the extraction, and the dried product may be extracted using the above solvent.
一般而言,依據菟絲子萃取物之應用形式,可視需要進一步乾燥步驟c)所獲得之菟絲子萃取物。舉例言之,若於步驟c)中選用之萃取溶劑為不具皮膚刺激性之甲醇或乙醇,且欲將所獲得之萃取物直接施用於如皮膚上時,則不須額外乾燥該萃取物。然而,若欲以口服之方式施用本發明之菟絲子萃取物時,則可利用一乾燥步驟(例如凍晶乾燥、減壓濃縮及/或通入氣體)以移除菟絲子萃取物中之有機溶劑,避免有機溶劑傷害身體。In general, depending on the application form of the Cuscuta extract, the Cuscuta extract obtained in the step c) can be further dried as needed. For example, if the extraction solvent selected in the step c) is methanol or ethanol which is not skin irritating, and the obtained extract is to be directly applied to, for example, the skin, the extract is not additionally dried. However, if the silk extract of the present invention is to be administered orally, a drying step (for example, freeze-drying, concentration under reduced pressure, and/or gas introduction) may be utilized to remove the organic solvent in the silk extract. Avoid organic solvents that can harm your body.
於本發明方法之一具體實施態樣中,係將菟絲子寄生於喜樹上;其後,自生長出之菟絲子分離取得液體,再對該液體進行萃取,得到含有喜樹鹼之菟絲子萃取物。較佳地,於萃取步驟中所使用之溶劑為甲醇,且以甲醇及該液體之總體積計,甲醇之用量為約30體積%至約99體積%;更佳地,甲醇之用量為約60體積%至約99體積%。或者,可先將該液體進行乾燥以獲得一乾燥物,再使用甲醇對該乾燥物進行萃取。可進一步對該菟絲子萃取物進行純化分離,以得到供製備醫藥組合物用之喜樹鹼。例如,可使用高效能液相層析法(High Performance Liquid Chromatography,HPLC)進行純化分離,得到高純度的喜樹鹼。In one embodiment of the method of the present invention, the dodder is parasitized on the camptotheca acuminata; thereafter, the liquid is separated from the grown dodder, and the liquid is extracted to obtain a dodder extract containing camptothecin. Preferably, the solvent used in the extraction step is methanol, and the amount of methanol is from about 30% by volume to about 99% by volume based on the total volume of methanol and the liquid; more preferably, the amount of methanol is about 60%. 5% by volume to about 99% by volume. Alternatively, the liquid may be first dried to obtain a dried product which is then extracted using methanol. The Cuscuta extract may be further purified and separated to obtain camptothecin for use in the preparation of a pharmaceutical composition. For example, purification separation can be carried out using High Performance Liquid Chromatography (HPLC) to obtain a high purity camptothecin.
喜樹鹼係一存在於喜樹中之化合物,其具有如下式(I)所示之化學結構,且被發現具有抗癌活性,例如,可用於治療消化系統腫瘤及黑色素腫瘤等。Camptothecin is a compound present in Camptotheca acuminata having a chemical structure represented by the following formula (I) and found to have anticancer activity, for example, for treating digestive tumors and melanoma tumors.
然而,喜樹鹼於喜樹中之含量濃度相當低,其於喜樹各部位之含量(乾重比)分別為:喜樹幼葉為0.01至0.1重量%;喜樹枝條為0.012重量%;喜樹心材為0.05重量%;喜樹根為0.02重量%;以及喜樹種子為0.02重量%,此可參見林業試驗所育林組研究員張淑華所著之報導(林業研究專訊,Vol. 13,No. 4,2006),該文獻全文併於此處以供參考。因此,若欲利用傳統之植物萃取方式,自喜樹中取得大量喜樹鹼,則即使耗費高成本以進行大規模栽種及萃取,所得之產率仍相當有限。然而,根據本發明方法,則可在保存喜樹實質上完整之情形下,經濟且簡便地藉由菟絲子自喜樹中提取喜樹鹼。However, the concentration of camptothecin in the camptotheca acuminata is quite low, and the content (dry weight ratio) of the camptothecin is 0.01 to 0.1% by weight of the young leaves of Camptotheca acuminata; 0.012% by weight of the camphor tree; It is 0.05% by weight of Camptotheca acuminata; 0.02% by weight of Camptotheca acuminata; and 0.02% by weight of Camptotheca acuminata seeds. This can be reported by Zhang Shuhua, a researcher at the Forestry Research Institute, Yulin Group (Forestry Research News, Vol. 13, No) 4, 2006), the entire disclosure of which is hereby incorporated by reference. Therefore, if a large amount of camptothecin is obtained from the self-grass tree by the conventional plant extraction method, the yield is still quite limited even if it is expensive to carry out large-scale planting and extraction. However, according to the method of the present invention, camptothecin can be extracted economically and simply by the eucalyptus eucalyptus tree in the case where the preserved eucalyptus is substantially intact.
於本發明方法之另一具體實施態樣中,係將菟絲子寄生於絞股藍;其後,自生長出之菟絲子分離取得含於其中之液體,再對該液體進行萃取,得到菟絲子萃取物。已知絞股藍具有抗腫瘤效益,尤其可以抗血癌。較佳地,於萃取步驟中所使用之溶劑為甲醇,且以甲醇及該液體之總體積計,甲醇之用量為約40體積%至約99體積%;更佳地,甲醇之用量為約60體積%至約99體積%。於此,可先將該液體進行乾燥以獲得一乾燥物,再使用甲醇對該乾燥物進行萃取。如後附實施例所示,以本發明方法將菟絲子寄生於絞股藍所得到之菟絲子萃取物,具有抗血癌功效,證明本發明方法可有效自絞股藍中提取抗血癌成分,提供具該抗血癌成分之菟絲子萃取物。In another embodiment of the method of the present invention, the dodder is parasitized to Gynostemma pentaphyllum; thereafter, the liquid contained therein is separated from the grown dodder, and the liquid is extracted to obtain a dodder extract. Gynostemma pentaphyllum is known to have anti-tumor benefits, especially against blood cancer. Preferably, the solvent used in the extraction step is methanol, and the amount of methanol is from about 40% by volume to about 99% by volume based on the total volume of methanol and the liquid; more preferably, the amount of methanol is about 60%. 5% by volume to about 99% by volume. Here, the liquid may be first dried to obtain a dried product, which is then extracted with methanol. As shown in the appended examples, the dodder seed obtained by parasitizing the dodder seed in the method of the present invention has anti-blood cancer effect, and proves that the method of the present invention can effectively extract anti-blood cancer components from Gynostemma pentaphyllum, and provide the anti-blood cancer component. Cuscuta extract.
本發明亦提供一種菟絲子萃取物,其可利用本發明上述方法製得。視所採用之寄主植物所含藥用成分之不同,提供含不同藥用成分之菟絲子萃取物。其中,當所採用之寄主植物為喜樹時,所提供之菟絲子萃取物係含有喜樹鹼;而當寄主植物為絞股藍時,所提供之菟絲子萃取物則含有抗血癌成分。The present invention also provides a dodder seed extract which can be obtained by the above method of the present invention. Cassia extract containing different medicinal ingredients is provided depending on the medicinal ingredients contained in the host plant used. Wherein, when the host plant used is Hibiscus, the provided dodder extract contains camptothecin; and when the host plant is Gynostemma pentaphyllum, the provided dodder extract contains anti-blood cancer components.
根據本發明,菟絲子除可用於製備藥性成分外,亦可用於檢測植物中是否含有藥性成分。其中,係將菟絲子寄生在一寄主植物上,且自該寄生菟絲子取得菟絲子萃取物,其後經由對該菟絲子萃取物進行生理活性試驗,藉由檢驗該萃取物是否含有所欲藥理活性成分,以得知該寄主植物是否含有該藥理活性成分。因此,本發明可以簡易手段進行活性篩選,毋須大量地進行栽種及繁複之萃取濃縮步驟,有利於藥性成分之檢測及新藥開發。According to the present invention, in addition to being used for the preparation of a medicinal ingredient, the dodder can also be used for detecting whether a medicinal ingredient is contained in a plant. Wherein, the dodder is parasitized on a host plant, and the dodder extract is obtained from the parasitic silk, and then the physiological activity test is performed on the dodder extract by testing whether the extract contains the desired pharmacologically active ingredient. It is known whether the host plant contains the pharmacologically active ingredient. Therefore, the present invention can perform active screening by a simple means, and it is not necessary to carry out a large number of planting and complicated extraction and concentration steps, which is advantageous for the detection of pharmaceutical ingredients and the development of new drugs.
本發明另提供一種從植物提取喜樹鹼及/或抗血癌成分之方法,包含:I)將菟絲子寄生於一植物上並於其上生長;II)收集該菟絲子中之液體;以及III)純化該液體以得到該喜樹鹼及/或抗血癌成分。本發明方法可用於檢測並進一步提取植物中之喜樹鹼及/或抗血癌成分。較佳地,步驟I)中之植物係喜樹或絞股藍,且於步驟III)中,係包含使用一溶劑以萃取由步驟II)所得之該液體,以得到一萃取物,其中該溶劑係選自以下群組:水、甲醇、乙醇、丙醇、丁醇、氯仿、及其組合;更佳地,該溶劑為甲醇。The invention further provides a method for extracting camptothecin and/or anti-blood cancer component from a plant, comprising: I) parasitizing and growing on a plant; II) collecting the liquid in the dodder; and III) purifying The liquid is used to obtain the camptothecin and/or anti-blood cancer component. The method of the invention can be used to detect and further extract camptothecin and/or anti-blood cancer components in plants. Preferably, the plant of step I) is camptotheca or gynostemma, and in step III), the solvent obtained by step II) is extracted using a solvent to obtain an extract, wherein the solvent is selected From the following groups: water, methanol, ethanol, propanol, butanol, chloroform, and combinations thereof; more preferably, the solvent is methanol.
於步驟III)中,可利用適宜之純化方法分離出喜樹鹼或抗血癌成分,以供製備醫藥組合物用。舉例言之,欲純化喜樹鹼時,可使用高效能液相層析法來進行。In step III), the camptothecin or anti-blood cancer component can be isolated by a suitable purification method for the preparation of a pharmaceutical composition. For example, to purify camptothecin, high performance liquid chromatography can be used.
本發明利用菟絲子來提供藥性成分之手段,具有許多優點。首先,本發明方法僅須採集寄生於寄主植物(即,藥用植物)上之菟絲子,即可得到所欲之藥性成分,而不會消耗或損傷寄主植物,可維持該植物之完整性,故不受寄主植物不易取得或瀕臨絕種等情況所限制。此外,只要寄主植物仍處於生長狀態下,便可透過本發明方法,持續地製得藥性成分,故不須大面積的土地以進行大規模及重複性的栽種,且可免除等待植物生長至成熟期的時間,徹底解決傳統草藥製備方法於植物採收後必須重新栽種的缺點。再者,由於以本發明方法所獲得之藥性成分業經菟絲子進行天然濃縮,故可減少植株乾燥、研磨、萃取、以及濃縮等繁複之生產步驟,達成簡化製程、節省溶劑及人力之效果,有效節省能源及土地之需求,降低成本。The present invention utilizes dodder seeds to provide a medicinal ingredient and has a number of advantages. First, the method of the present invention only needs to collect the dodders parasitic on the host plant (ie, the medicinal plant) to obtain the desired medicinal component without consuming or damaging the host plant, thereby maintaining the integrity of the plant. Not restricted by host plants that are difficult to obtain or endangered. In addition, as long as the host plant is still in a growing state, the medicinal ingredient can be continuously produced by the method of the present invention, so that a large area of land is not required for large-scale and repetitive planting, and the plant is allowed to grow to maturity. The time of the period completely solves the shortcomings of traditional herbal preparation methods that must be replanted after plant harvesting. Furthermore, since the medicinal component obtained by the method of the present invention is naturally concentrated by the dodder, the complicated production steps such as drying, grinding, extraction, and concentration of the plant can be reduced, and the process of simplifying the process, saving the solvent and manpower can be achieved, and the effective saving can be achieved. Energy and land demand, reducing costs.
茲以下列具體實施態樣以進一步例示說明本發明。其中該些實施態樣僅提供作為說明,而非用以限制本發明之範疇。The invention is further illustrated by the following specific embodiments. The embodiments are provided for illustrative purposes only and are not intended to limit the scope of the invention.
實驗A、製備寄生於喜樹之日本菟絲子之萃取物Experiment A, preparation of extracts of Japanese dodders parasitic on the eucalyptus
首先,採取約15公分之日本菟絲子(Cuscuta japonica Choisy var. japonica),將其寄生於喜樹(Camptotheca acuminate )上,並使其於喜樹上生長。於寄生期間,日本菟絲子莖上會產生吸器,並插入喜樹之韌皮部,以吸取養分。在日本菟絲子寄生達至少10天之後,採取日本菟絲子之新生組織,並將其切成約1公分之片段,再置入一離心管中,以離心機(DENVILLE 260D,購自DENVILLE scientific公司)於10,000轉/分鐘之轉速下離心5分鐘之後,收集經離心後所得之液體,即可取得日本菟絲子韌皮部汁液。接著,乾燥該液體,以獲得一乾燥物,再使用甲醇萃取該乾燥物,即可製得含有喜樹韌皮部之成分的日本菟絲子萃取物。First, about 15 cm of Cuscuta japonica Choisy var. japonica was taken and parasitized on Camptotheca acuminate and allowed to grow on the camptotheca. During the parasitic period, a straw is produced on the stem of the Japanese stalk, and inserted into the phloem of the camptothelium to absorb nutrients. After at least 10 days of parasitization of Cuscuta in Japan, the new tissue of the Japanese Cuscuta was taken and cut into pieces of about 1 cm, which was placed in a centrifuge tube and centrifuged (DENVILLE 260D, purchased from DENVILLE Scientific). After centrifugation at a speed of 10,000 rpm for 5 minutes, the liquid obtained by centrifugation was collected to obtain a phloem sap of Japanese scorpion. Next, the liquid is dried to obtain a dried product, and the dried product is extracted with methanol to obtain a Japanese dodder extract containing a component of the phloem of the camptotheca.
實驗B、測量日本菟絲子萃取物中喜樹鹼之含量Experiment B, measuring the content of camptothecin in Japanese dodder extract
將實施例1中所製得之日本菟絲子萃取物,以高效能液相層析儀(High Performance Liquid Chromatography,HPLC,L-2455,購自HITACHI公司)分析萃取物中喜樹鹼(camptothecin)之含量。液相層析儀之分析條件為:色譜管柱:KANTO化學公司,RP-18 GP Aqua 250-4.6(5微米);檢測波長:254奈米;流動相:乙腈(acetonitrile,40%)-30毫莫耳濃度之乙酸銨(Ammonium acetate,60%);進樣量:10微升;流速:1毫升/分鐘;洗脫時間:10分鐘。使用喜樹鹼標準品(購自Sigma-Aldrich化學公司;C9911-100MG)與該萃取物進行HPLC比較分析,以測得該萃取物中之喜樹鹼濃度,結果係如第1圖所示。The Japanese Cuscuta extract prepared in Example 1 was analyzed for the camptothecin in the extract by High Performance Liquid Chromatography (HPLC, L-2455, available from HITACHI). content. The analytical conditions of the liquid chromatograph are: chromatographic column: KANTO Chemical Company, RP-18 GP Aqua 250-4.6 (5 μm); detection wavelength: 254 nm; mobile phase: acetonitrile (40%)-30 Ammonium acetate (60%); injection volume: 10 μl; flow rate: 1 ml/min; elution time: 10 minutes. The camptothecin standard (purchased from Sigma-Aldrich Chemical Co.; C9911-100MG) was subjected to HPLC comparative analysis with the extract to determine the camptothecin concentration in the extract, and the results are shown in Fig. 1.
HPLC分析圖譜之結果顯示,每100微升之日本菟絲子韌皮部汁液中含有約3微克之喜樹鹼(即3重量/體積%(3微克/100微升))。The results of the HPLC analysis showed that about 3 μg of camptothecin (i.e., 3 wt/vol% (3 μg/100 μl)) was contained per 100 μl of Japanese dodder phloem sap.
上述結果顯示,相較於傳統栽種方法,本發明之製備方法可有效率且經濟地製備喜樹鹼。The above results show that the preparation method of the present invention can efficiently and economically prepare camptothecin compared to the conventional planting method.
首先,採取約15公分之日本菟絲子,將其寄生於絞股藍(Gynostemma pentaphyllum )上,並使其於絞股藍上生長。於寄生期間,日本菟絲子莖上會產生吸器並插入絞股藍之韌皮部以吸取養分。在菟絲子寄生達至少10天之後,採取菟絲子之新生組織,並將其切成約1公分之片段,再置入一離心管中,以離心機(DENVILLE 260D,購自DENVILLE scientific公司)於10,000轉/分鐘之轉速下離心5分鐘之後,收集經離心後所得之液體,即可取得日本菟絲子韌皮部汁液。接著,乾燥該液體,以獲得一乾燥物,再使用甲醇萃取該乾燥物,即可製得含有絞股藍韌皮部之成分的日本菟絲子萃取物。First, about 15 cm of Japanese dodder was used, which was parasitized on Gynostemma pentaphyllum and allowed to grow on Gynostemma pentaphyllum. During the parasitization, the stalk of the Japanese stalk is produced and inserted into the phloem of Gynostemma pentaphyllum to absorb nutrients. After at least 10 days of parasitization of the dodder, the new tissue of the dodder was taken and cut into pieces of about 1 cm, and then placed in a centrifuge tube, centrifuged (DENVILLE 260D, purchased from DENVILLE scientific) at 10,000 rpm. After centrifugation for 5 minutes at a speed of /min, the liquid obtained by centrifugation was collected to obtain a phloem sap of Japanese scorpion. Next, the liquid is dried to obtain a dried product, and the dried product is extracted with methanol to obtain a Japanese dodder extract containing a component of the phloem of Gynostemma pentaphyllum.
實驗D、製備寄生於榕樹之日本菟絲子之萃取物Experiment D, preparation of extracts of Japanese dodders parasitic on eucalyptus
首先,採取約15公分之日本菟絲子,將其寄生於榕樹(Ficus microcarpa )上,並使其於榕樹上生長。於寄生期間,日本菟絲子莖上會產生吸器並插入榕樹之韌皮部以吸取養分。在菟絲子寄生至少10天之後,採取菟絲子之新生組織,並將其切成約1公分之片段,再置入一離心管中,以離心機(DENVILLE 260D,購自DENVILLE scientific公司)於10,000轉/分鐘之轉速下離心5分鐘之後,收集經離心後所得之液體,即可取得日本菟絲子韌皮部汁液。接著,乾燥該液體,以獲得一乾燥物,再使用甲醇萃取該乾燥物,即可製得含有榕樹韌皮部之成分的日本菟絲子萃取物。First, take about 15 cm of Japanese dodder, parasitize it on the eucalyptus ( Ficus microcarpa ) and grow it on the eucalyptus. During the parasitization, a straw is produced on the stem of the Japanese stalk and inserted into the phloem of the eucalyptus to absorb nutrients. After at least 10 days of dodder parasitization, the new tissue of the dodder was taken and cut into pieces of about 1 cm, which was placed in a centrifuge tube and centrifuged (DENVILLE 260D, purchased from DENVILLE Scientific) at 10,000 rpm. After centrifugation for 5 minutes at a minute speed, the liquid obtained by centrifugation is collected to obtain a phloem sap of Japanese scorpion. Next, the liquid is dried to obtain a dried product, and the dried product is extracted with methanol to obtain a Japanese dodder extract containing a component of the phloem of the eucalyptus.
實驗E、檢測寄主植物絞股藍及榕樹之藥性成分Experiment E. Detecting the medicinal components of the host plant Gynostemma pentaphyllum and Eucalyptus
於本實驗中,利用人類骨髓性血癌細胞株HL-60(Human Leukemia cell line-60)(購自食品工業研究所)進行細胞毒殺及誘導細胞凋亡(apotosis)的試驗,以篩檢自實驗C及實驗D中製得之日本菟絲子萃取物,藉此鑑定絞股藍或榕樹中是否含有抗血癌之藥性成分。In this experiment, human bone marrow cancer cell line HL-60 (Human Leukemia cell line-60) (purchased from the Food Industry Research Institute) was used for cell cytotoxicity and apoptosis induction (apotosis) test to screen from the experiment. C and the Japanese Cuscuta extract prepared in Experiment D, thereby identifying whether Gynostemma pentaphyllum or Eucalyptus contains a drug component resistant to blood cancer.
首先,分別將實驗C及實驗D中製得之日本菟絲子萃取物溶於二甲基亞碸中,並製備為0至40微克/毫升之濃度,作為血癌細胞生理活性測試之樣品。分別將1×105 個人類骨髓性血癌細胞株HL-60種於一24孔盤中,其中每一孔之體積為1毫升,並分別投予濃度為0至40微克/毫升之樣品至孔中。將該24孔盤置於含有5%二氧化碳之37℃培養箱培養48小時後,收集每一孔中之懸浮細胞並轉移至一流式細胞術(fluorescence activated cell sorter,FACS)專用小管中,以離心機(DENVILLE 260D,購自DENVILLE scientific)於900轉/分鐘之轉速下離心5分鐘之後,去除培養基,用Dulbecco’s磷酸鹽緩衝液(Dulbecco’s phosphate Buffered Saline,D-PBS)清洗細胞兩次,添加100至500微升染劑(碘化丙啶(propidium iodide),濃度為4微克/毫升)),在4℃下避光30分鐘後,最後以流式細胞儀(flow cytometry,FACSCanto,購自Becton Dickinson美商必帝股份有限公司)檢測經處理之懸浮細胞中,人類骨髓性血癌細胞的存活率。結果係如第2圖所示。First, the Japanese scorpion extract prepared in Experiment C and Experiment D was dissolved in dimethyl sulfoxide, respectively, and prepared at a concentration of 0 to 40 μg/ml as a sample for blood cell physiological activity test. 1×10 5 human bone marrow blood cancer cell line HL-60 was seeded in a 24-well plate, and the volume of each well was 1 ml, and a sample with a concentration of 0 to 40 μg/ml was administered to the well. in. After culturing the 24-well plate in a 37 ° C incubator containing 5% carbon dioxide for 48 hours, the suspension cells in each well were collected and transferred to a special tube for fluorescence activated cell sorter (FACS) to centrifuge. The machine (DENVILLE 260D, purchased from DENVILLE scientific) was centrifuged at 900 rpm for 5 minutes, the medium was removed, and the cells were washed twice with Dulbecco's phosphate Buffered Saline (D-PBS) and 100 was added. 500 microliters of dye (propidium iodide, concentration 4 μg/ml)), protected from light for 30 minutes at 4 ° C, and finally flow cytometry (FACSCanto, purchased from Becton Dickinson) American Business Co., Ltd.) detects the survival rate of human bone marrow blood cancer cells in treated suspension cells. The results are shown in Figure 2.
實驗結果顯示,寄生於絞股藍之日本菟絲子的萃取物,具有毒殺人類骨髓性血癌細胞HL-60之效果,且在15微克/毫升濃度下,可毒殺50%之人類骨髓性血癌細胞HL-60;而寄生於榕樹之日本菟絲子的萃取物,則無毒殺人類骨髓性血癌細胞HL-60之效果。The experimental results show that the extract of Japanese dodder, which is parasitic on Gynostemma pentaphyllum, has the effect of poisoning human bone marrow blood cancer cell line HL-60, and can poison 50% of human bone marrow blood cancer cell line HL-60 at a concentration of 15 μg/ml; The extract of Japanese Cuscuta, which is parasitic on eucalyptus, is non-toxic to kill human bone marrow blood cancer cells HL-60.
接著,分別將1 x 105 個人類骨髓性血癌細胞株HL-60種於一24孔盤中,並分別投予15微克/毫升之萃取物樣品至各孔中,並重複上述培養離心清洗等步驟,最後以流式細胞儀(flow cytometry,FACSCanto,購自Becton Dickinson美商必帝股份有限公司)進行細胞週期分析。結果係如第3圖及第4圖所示。Next, 1 x 10 5 human bone marrow blood cancer cell line HL-60 was seeded in a 24-well plate, and 15 μg/ml of the extract sample was administered to each well, and the above-mentioned culture centrifugal washing was repeated. The procedure was followed by cell cycle analysis by flow cytometry (FACSCanto, purchased from Becton Dickinson). The results are shown in Figures 3 and 4.
結果顯示,該萃取物可誘導約10%之人類骨髓性血癌細胞HL-60進行細胞凋亡(apotosis),因此,可確定絞股藍中含有抗血癌之藥性成分。As a result, the extract induced about 10% of human bone marrow blood cancer cell line HL-60 to undergo apotosis, and therefore, it was confirmed that Gynostemma pentaphyllum contains a drug component resistant to blood cancer.
另一方面,寄生於榕樹之日本菟絲子的萃取物並無毒殺人類骨髓性血癌細胞HL-60之作用,且如第3圖及第4圖所示,該萃取物並無明顯誘導人類骨髓性血癌細胞HL-60進行細胞凋亡之效果。因此,試驗顯示榕樹中並不含有抗血癌之藥性成分。On the other hand, the extract of Japanese dodder, which is parasitic on eucalyptus, does not poison the human bone marrow blood cancer cell line HL-60, and as shown in Fig. 3 and Fig. 4, the extract does not significantly induce human bone marrow blood cancer. The effect of cell HL-60 on apoptosis. Therefore, tests have shown that eucalyptus does not contain medicinal components that are resistant to blood cancer.
實驗E之結果顯示,本發明方法可用於有效率且方便地篩選及/或提取植物中之藥性成分。The results of Experiment E show that the method of the present invention can be used to efficiently and conveniently screen and/or extract medicinal ingredients in plants.
由實施例1及實施例2之結果可知,本發明方法所製備之菟絲子萃取物中含有寄主植物的藥性成分,故本發明之菟絲子萃取物的製備方法可用於大規模地生產各種藥用植物之藥性成分,例如,植物二次代謝物、化合物、醣類、胜肽、蛋白質或酵素等。此外,本發明方法可提供含有寄主植物成分之菟絲子萃取物樣本,以供生理活性試驗用,從而有效率地進行植物中活性成分之篩選,故對於新藥開發相當有利。It can be seen from the results of Example 1 and Example 2 that the dodder extract prepared by the method of the present invention contains the medicinal component of the host plant, so the preparation method of the dodder extract of the present invention can be used for large-scale production of various medicinal plants. A pharmaceutical ingredient, for example, a plant secondary metabolite, a compound, a saccharide, a peptide, a protein or an enzyme. In addition, the method of the present invention can provide a sample of a silkworm extract containing a host plant component for physiological activity testing, thereby efficiently screening the active ingredients in the plant, and is therefore quite advantageous for the development of new drugs.
上述實施例僅係用以例示說明本發明之原理及功效,而非用於限制本發明。任何熟於此項技藝之人士均可在不違背本發明之技術原理及精神的情況下,對上述實施例進行修改及變化。因此,本發明之權利保護範圍應如後述之申請專利範圍所列者。The above embodiments are merely illustrative of the principles and effects of the invention and are not intended to limit the invention. Modifications and variations of the above-described embodiments can be made by those skilled in the art without departing from the spirit and scope of the invention. Therefore, the scope of protection of the present invention should be as set forth in the scope of the patent application described hereinafter.
第1圖所示為喜樹鹼標準品與寄生於喜樹之日本菟絲子之萃取物的HPLC分析圖譜;Figure 1 shows the HPLC analysis of the camptothecin standard and the extract of the Japanese scorpion parasitized by Camptotheca acuminata;
第2圖所示為寄生於絞股藍之日本菟絲子之萃取物,對於人類骨髓性血癌細胞HL-60之毒殺效果的統計曲線圖;Figure 2 is a statistical graph showing the poisoning effect of the extract of Japanese scorpion, which is parasitic on Gynostemma pentaphyllum, on human bone marrow blood cancer cell line HL-60;
第3圖所示為寄生於絞股藍或榕樹之日本菟絲子的萃取物,對於人類骨髓性血癌細胞HL-60之細胞週期之影響的流式細胞儀分析圖;以及Figure 3 is a flow cytometric analysis of the effects of the extract of Japanese dodder, which is parasitic on Gynostemma pentaphyllum or Eucalyptus, on the cell cycle of human myeloid blood cancer cell line HL-60;
第4圖所示為寄生於絞股藍或榕樹之日本菟絲子的萃取物,對於人類骨髓性血癌細胞HL-60之細胞週期之影響的統計直條圖。Figure 4 is a statistical bar graph showing the effect of the extract of Japanese Cuscuta, which is parasitic on Gynostemma pentaphyllum or Eucalyptus, on the cell cycle of human myeloid blood cancer cell line HL-60.
Claims (17)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW99116803A TWI382845B (en) | 2010-05-26 | 2010-05-26 | Cuscuta sp. extract and method for preparing the same and uses of cuscuta sp. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW99116803A TWI382845B (en) | 2010-05-26 | 2010-05-26 | Cuscuta sp. extract and method for preparing the same and uses of cuscuta sp. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201141497A TW201141497A (en) | 2011-12-01 |
| TWI382845B true TWI382845B (en) | 2013-01-21 |
Family
ID=46764738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW99116803A TWI382845B (en) | 2010-05-26 | 2010-05-26 | Cuscuta sp. extract and method for preparing the same and uses of cuscuta sp. |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI382845B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200509955A (en) * | 2003-03-28 | 2005-03-16 | Nuliv Biomedicine Inc | Pharmaceutical composition for prophylaxis or treatment of osteoporosis, and method to prepare the same |
| TW200918350A (en) * | 2007-10-29 | 2009-05-01 | Teckson Chemicals Company | Method of manufacturing decorative board structure having three dimensional patterns |
-
2010
- 2010-05-26 TW TW99116803A patent/TWI382845B/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200509955A (en) * | 2003-03-28 | 2005-03-16 | Nuliv Biomedicine Inc | Pharmaceutical composition for prophylaxis or treatment of osteoporosis, and method to prepare the same |
| TW200918350A (en) * | 2007-10-29 | 2009-05-01 | Teckson Chemicals Company | Method of manufacturing decorative board structure having three dimensional patterns |
Non-Patent Citations (1)
| Title |
|---|
| 楊士平;李慶國,喜樹鹼及其衍生物的歷史回顧及展望,化學,2009,第67卷第1期 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201141497A (en) | 2011-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sathasivam et al. | Thrombocyte counts in mice after the administration of papaya leaf suspension | |
| Zhang et al. | Promoting role of an endophyte on the growth and contents of kinsenosides and flavonoids of Anoectochilus formosanus Hayata, a rare and threatened medicinal Orchidaceae plant | |
| CN106086147A (en) | Fungal elicitor is utilized to induce the method extracting betulic acid from Inonqqus obliquus | |
| CN100558236C (en) | Extract of Baiqian and its preparation method and application | |
| CN113952331B (en) | Garcinia macrophylla seed extract with anti-tumor activity and preparation method thereof | |
| CN101069702A (en) | Efficient, low-toxic and environment-protective plant insect-killing extract | |
| TWI382845B (en) | Cuscuta sp. extract and method for preparing the same and uses of cuscuta sp. | |
| CN102086187B (en) | Method for extracting and separating out oligomeric proanthocyanidins from Yunnan pine barks | |
| CN102775375A (en) | Chromone compound, preparation method and application of chromone compound, anti-aids pharmaceutical composition prepared from chromone compound and preparation of anti-aids pharmaceutical composition | |
| CN105481817A (en) | Isocoumarin compound, and preparation method and application thereof | |
| CN103113196B (en) | Glechoma longituba phenol, and preparation method and application thereof | |
| CN105348247A (en) | Isocoumarin compound, and preparation method and application thereof | |
| CN104447330B (en) | A kind of method preparing antiseptic-germicide from pine needle | |
| CN109833337B (en) | A kind of Momordica charantia compound that inhibits the immune response of pests and its high-efficiency preparation method and application | |
| CN110178857B (en) | The use of seabuckthorn endophytic fungus strain SJ1 fermentation extract | |
| CN110393712B (en) | Anti-tumor effective part extracted from cannabis sativa leaf herba lycopi and preparation method and application thereof | |
| Domínguez et al. | Production of honokiol and magnolol in suspension cultures of Magnolia dealbata Zucc | |
| CN101385471A (en) | Active material extracted from Acutangular Anisodus root and uses thereof | |
| CN102491869B (en) | Rheumlikiangense extract with liver injury protection activity and preparation method thereof | |
| CN112174848B (en) | A kind of oleoyl ethanolamine compound with antibacterial activity in mulberry, preparation method and application thereof | |
| CN117185980B (en) | Azacyclic anthraquinone compound with tobacco mosaic virus resistance activity, and preparation method and application thereof | |
| CN104789613A (en) | Method for extracting and separating bacteriostatic active components from fermentation broth containing spiraea salicifolia endophytic fungi | |
| CN115894180B (en) | Method for separating mycotoxin from metabolite of black spot bacteria of ginseng | |
| CN102318651B (en) | Nematicidal extract of radix-polygoni multiflori and preparation method thereof | |
| Isah | Should Seed Be an Alternative Source of Camptothecin From Nothapodytes nimmoniana and Chonemorpha fragrance? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |